阿莫西林/克拉维酸钾联合常规抗结核药治疗耐多药肺结核的疗效观察
目的：探讨阿莫西林/克拉维酸钾联合常规抗结核药治疗耐多药肺结核（multidrug resistance tuberculosis,MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者按随机数字表法分为观察组103例和对照组102例。对照组患者给予吡嗪酰胺、乙胺丁醇、对氨基水杨酸异烟肼、利福喷丁和左氧氟沙星,观察组患者在对照组治疗的基础上加用阿莫西林/克拉维酸钾,2组疗程均为12个月。观察患者的痰菌阴转、病灶吸收、空洞闭合和不良反应发生情况。结果：治疗3个月后,2组患者痰菌阴转率的差异无统计学意义（P〉0.05）;治疗6、9、12个月后,观察组患者痰菌阴转率分别为68.93%（...
Saved in:
| Published in | 中国医院用药评价与分析 no. 9; pp. 1142 - 1144 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
河南省胸科医院药剂科,河南郑州,450000
2015
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1672-2124 |
| DOI | 10.14009/j.issn.1672-2124.2015.09.003 |
Cover
| Abstract | 目的：探讨阿莫西林/克拉维酸钾联合常规抗结核药治疗耐多药肺结核（multidrug resistance tuberculosis,MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者按随机数字表法分为观察组103例和对照组102例。对照组患者给予吡嗪酰胺、乙胺丁醇、对氨基水杨酸异烟肼、利福喷丁和左氧氟沙星,观察组患者在对照组治疗的基础上加用阿莫西林/克拉维酸钾,2组疗程均为12个月。观察患者的痰菌阴转、病灶吸收、空洞闭合和不良反应发生情况。结果：治疗3个月后,2组患者痰菌阴转率的差异无统计学意义（P〉0.05）;治疗6、9、12个月后,观察组患者痰菌阴转率分别为68.93%（71/103）、74.76%（77/103）和81.55%（84/103）,均明显高于对照组的50.98%（52/102）、55.88%（57/102）和60.78%（62/102）,差异有统计学意义（P〈0.05）;疗程结束时观察组与对照组患者的病灶吸收总有效率分别为88.35%（91/103）和66.67%（68/102）,空洞闭合总有效率分别为84.47%（87/103）和64.71%（66/102）,观察组均明显优于对照组,差异均有统计学意义（P〈0.05）。结论：阿莫西林/克拉维酸钾联合常规抗结核药治疗MDRTB安全、有效,但短期疗效优势不明显。 |
|---|---|
| AbstractList | 目的：探讨阿莫西林/克拉维酸钾联合常规抗结核药治疗耐多药肺结核（multidrug resistance tuberculosis,MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者按随机数字表法分为观察组103例和对照组102例。对照组患者给予吡嗪酰胺、乙胺丁醇、对氨基水杨酸异烟肼、利福喷丁和左氧氟沙星,观察组患者在对照组治疗的基础上加用阿莫西林/克拉维酸钾,2组疗程均为12个月。观察患者的痰菌阴转、病灶吸收、空洞闭合和不良反应发生情况。结果：治疗3个月后,2组患者痰菌阴转率的差异无统计学意义（P〉0.05）;治疗6、9、12个月后,观察组患者痰菌阴转率分别为68.93%（71/103）、74.76%（77/103）和81.55%（84/103）,均明显高于对照组的50.98%（52/102）、55.88%（57/102）和60.78%（62/102）,差异有统计学意义（P〈0.05）;疗程结束时观察组与对照组患者的病灶吸收总有效率分别为88.35%（91/103）和66.67%（68/102）,空洞闭合总有效率分别为84.47%（87/103）和64.71%（66/102）,观察组均明显优于对照组,差异均有统计学意义（P〈0.05）。结论：阿莫西林/克拉维酸钾联合常规抗结核药治疗MDRTB安全、有效,但短期疗效优势不明显。 R974; 目的：探讨阿莫西林／克拉维酸钾联合常规抗结核药治疗耐多药肺结核（ multidrug resistance tuberculosis ，MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者按随机数字表法分为观察组103例和对照组102例。对照组患者给予吡嗪酰胺、乙胺丁醇、对氨基水杨酸异烟肼、利福喷丁和左氧氟沙星，观察组患者在对照组治疗的基础上加用阿莫西林／克拉维酸钾，2组疗程均为12个月。观察患者的痰菌阴转、病灶吸收、空洞闭合和不良反应发生情况。结果：治疗3个月后，2组患者痰菌阴转率的差异无统计学意义（P＞0.05）；治疗6、9、12个月后，观察组患者痰菌阴转率分别为68.93％（71／103）、74.76％（77／103）和81.55％（84／103），均明显高于对照组的50.98％（52／102）、55.88％（57／102）和60.78％（62／102），差异有统计学意义（P＜0.05）；疗程结束时观察组与对照组患者的病灶吸收总有效率分别为88.35％（91／103）和66.67％（68／102），空洞闭合总有效率分别为84.47％（87／103）和64.71％（66／102），观察组均明显优于对照组，差异均有统计学意义（P＜0.05）。结论：阿莫西林／克拉维酸钾联合常规抗结核药治疗MDR-TB安全、有效，但短期疗效优势不明显。 |
| Abstract_FL | OBJECTIVE:To probe into the clinical efficacy and adverse drug reaction of amoxycillin /clavulanate potassium combined with conventional anti-TB drugs in treatment of multidrug resistance tuberculosis ( MDR-TB ) . METHODS:205 MDR-TB patients were divided into treatment group (103 patients) and control group (102 patients) by random number table .The control group was given amoxycillin , ethambutol , isoniazid aminosalicylate , rifapentine and levofloxacin , the observation group received amoxycillin/clavulanate potassiumthe based on the same treatment regimen of the control group .The treatment course of 2 groups was 12 months.The changes of sputum negative conversion, focal absorption, cavity, the improved clinical symptoms and negative ADR consequences were closely observed in two groups .RESULTS:After the treatment of 3 months, there was no statistically significant difference of the sputum negative conversion rate in 2 groups ( P>0.05 ) .In the treatment group , the sputum negative rate at the sixth, ninth and twelfth month were respectively 68.93%(71/103), 74.76%(77/103) and 81.55%(84/103), which was significantly higher than that in the control group 50.98%( 52/102 )、55.88%( 57/102 ) and 60.78%(62/102) respectively, with statistically significant difference ( P >0.05).At the end of the treatment, the focal absorption rate of treatment group and control group was respectively 88.35%(91/103) and 66.67%(68/102), the cavity closure rate of treatment group and control group were respectively 84.47%(87/103) and 64.71%(66/102);the above-mentioned indexes in the treatment group were all significantly better than that in the control group , with significant difference ( P<0.05 ) .CONCLUSIONS:It is safe and effective to use amoxycillin/clavulanate potassium in the treatment of MDR-TB, but still have few significant advantages in the short-term efficacy. |
| Author | 郭蕊 焦雪峰 陈爽 罗琳 |
| AuthorAffiliation | 河南省胸科医院药剂科,河南郑州450000 |
| AuthorAffiliation_xml | – name: 河南省胸科医院药剂科,河南郑州,450000 |
| Author_FL | GUO Rui JIAO Xuefeng LUO Lin CHEN Shuang |
| Author_FL_xml | – sequence: 1 fullname: GUO Rui – sequence: 2 fullname: JIAO Xuefeng – sequence: 3 fullname: CHEN Shuang – sequence: 4 fullname: LUO Lin |
| Author_xml | – sequence: 1 fullname: 郭蕊 焦雪峰 陈爽 罗琳 |
| BookMark | eNo9UMtKw0AUnUUFa-1PCO5MOjOZTCZLKb6g4KY7F2Umj9qiqTaI1pWWFqpFKb4qXagLpQsXBXERLNivSTL9CyMV7-Zwzz3nXDgLIOXVPAeAZQRVRCA0c1W14vueiqiBFYwwUTFEugpNFUItBdL__DzI-n5FQKwbEGONpMHO9HEir9_l2yR66ufCdjfqXsTjz2k7mN58y_O7sNcJg0AOW9FlPx7fRi-BvBpFH-P4oS_PeuHrIFll82t2igethI_uO3LYDEfPi2DO5Xu-k_3DDCiurxXzm0phe2Mrv1pQLEo0hVCDawJahHPBbBtBUzjMIQ4lFtG5awphIZsQRinkBmUGFwZFWHBGHWHbGtMyYGUWe8w9l3vlUrV2VPeSh6XTciOZg2rDPfktBJpJHYl8aSa3dmte-bCSGA7qlX1eb5QoNRghJtO1H6oJh1c |
| ClassificationCodes | R974 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.14009/j.issn.1672-2124.2015.09.003 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Observation of Amoxycillin/Clavulanate Potassium Combined with Conventional Anti-TB Drugs in Treatment of Multidrug Resistance Tuberculosis |
| DocumentTitle_FL | Observation of Amoxycillin/Clavulanate Potassium Combined with Conventional Anti-TB Drugs in Treatment of Multidrug Resistance Tuberculosis |
| EndPage | 1144 |
| ExternalDocumentID | zgyyyypjyfx201509003 667844985 |
| GrantInformation_xml | – fundername: 常州四药临床药学科研基金 funderid: (CZSYJJ14009) |
| GroupedDBID | 2RA 92L ALMA_UNASSIGNED_HOLDINGS CDYEO CQIGP W91 ~WA 2B. 4A8 92I 93N ABDBF ACUHS EOJEC OBODZ PSX TCJ TUS |
| ID | FETCH-LOGICAL-c643-467a3b0c4aab8dd109be8e4e64c45af9bbc1d448660a7687ab7612ba86ebdd383 |
| ISSN | 1672-2124 |
| IngestDate | Thu May 29 04:11:26 EDT 2025 Wed Feb 14 10:21:24 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 9 |
| Keywords | 痰菌阴转率 Amoxycillin/clavulanate potassium 耐多药肺结核 Sputum negative conversion 病灶吸收 阿莫西林/克拉维酸钾 空洞闭合 Focal absorption Multidrug resistance tuberculosis Cavity closure |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c643-467a3b0c4aab8dd109be8e4e64c45af9bbc1d448660a7687ab7612ba86ebdd383 |
| Notes | OBJECTIVE： To probe into the clinical efficacy and adverse drug reaction of amoxycillin / clavulanate potassium combined with conventional anti- TB drugs in treatment of multidrug resistance tuberculosis（ MDR-TB）.METHODS： 205 MDR-TB patients were divided into treatment group（ 103 patients） and control group（ 102 patients）by random number table. The control group was given amoxycillin,ethambutol,isoniazid aminosalicylate,rifapentine and levofloxacin,the observation group received amoxycillin / clavulanate potassiumthe based on the same treatment regimen of the control group. The treatment course of 2 groups was 12 months. The changes of sputum negative conversion,focal absorption,cavity,the improved clinical symptoms and negative ADR consequences were closely observed in two groups. RESULTS： After the treatment of 3 months,there was no statistically significant difference of the sputum negative conversion rate in 2 groups（ P 0. 05）. In the treatment group,the sputum negative rate at the sixth,ninth and twelfth |
| PageCount | 3 |
| ParticipantIDs | wanfang_journals_zgyyyypjyfx201509003 chongqing_primary_667844985 |
| PublicationCentury | 2000 |
| PublicationDate | 2015 |
| PublicationDateYYYYMMDD | 2015-01-01 |
| PublicationDate_xml | – year: 2015 text: 2015 |
| PublicationDecade | 2010 |
| PublicationTitle | 中国医院用药评价与分析 |
| PublicationTitleAlternate | Evaluation and Analysis of Drug-use in Hospitals of China |
| PublicationTitle_FL | Evaluation and Analysis of Drug-Use in Hospitals of China |
| PublicationYear | 2015 |
| Publisher | 河南省胸科医院药剂科,河南郑州,450000 |
| Publisher_xml | – name: 河南省胸科医院药剂科,河南郑州,450000 |
| SSID | ssib025702234 ssib017477209 ssib001103637 ssib051368574 ssib000405437 ssib001215202 ssib036441963 ssib006563103 ssib057928707 |
| Score | 2.0041053 |
| Snippet | 目的：探讨阿莫西林/克拉维酸钾联合常规抗结核药治疗耐多药肺结核（multidrug resistance tuberculosis,MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者按随机数字... R974; 目的：探讨阿莫西林／克拉维酸钾联合常规抗结核药治疗耐多药肺结核（ multidrug resistance tuberculosis ，MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 1142 |
| SubjectTerms | 病灶吸收 痰菌阴转率 空洞闭合 耐多药肺结核 阿莫西林/克拉维酸钾 |
| Title | 阿莫西林/克拉维酸钾联合常规抗结核药治疗耐多药肺结核的疗效观察 |
| URI | http://lib.cqvip.com/qk/86765X/201509/667844985.html https://d.wanfangdata.com.cn/periodical/zgyyyypjyfx201509003 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVCAB databaseName: Nutrition and Food Sciences Database issn: 1672-2124 databaseCode: DYU dateStart: 20150101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.cabidigitallibrary.org/product/zd omitProxy: true ssIdentifier: ssib001215202 providerName: CAB International |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NT9RAFG8AE-PFaNSIqOHgnEihH9PpzHEKJYRET5BgPGw6_YB4WFAhEU5KIEGJhviF4aAeNBw8kBgPG0nkr9nd8l_43rSUkhCibjaTmenrb2beazu_aWfeGMYdlVrKoVFq-k7imFREtsmdxDOz2I6yGHpwn-La4bv32MQ0nZzxZnp6J2uzlpYW1XC8cuq6kv-xKuSBXXGV7D9YtgKFDIiDfSEEC0P4VzYmoSCCk2CchJzwkMgAI9LTOYyIkGgHuCT0CId_gJkQckFCnwQBCSgiwKGAayiHBKGGsomgeJawCOcYAQGUAXCfcKpxJIIXOMLFHGmVMnyMSF2BwMGjICOYFubFvAoElJQIWROGCAjL0wB9lMRCKxwIPV2xoj6OBhwn4sQcRRJSPF2O6YZAY3WEj-oqQWMFkY7GpETyEzWBEIujWkV-iQPqDXWhnB3ptvrSo7Xo6qK4rpocQmQAkUyXFRAptRpdElhDZfFctw3CYEyLQwULjYKGArf-OqZYilr2Hcx3TGACtHbbiFrfgKuWazwDkvTUPgyeqkJ3Yog6XKHiNERP--S13OPOu5pSyYB1UCq412ucc_DdFA4Q7k_XqDuQ8xoVBdrnsnoaNziuuYIDno9b0B2lYeAK47BjV2-4-SEwy-pZ7iKvFseu3DwbdzbQTtCrFpw3yFH7Rs5qHbo5mZtvzj4C8qbX0jWzqDlbo31Tl4yL5XhtUBY332WjZ2XuivHg8ONB_vp7_u2g82l7pL2-2dl80d3_ebjeOnzzO3_-rr210W618t21zsvt7v7bzpdW_mqv82O_-2E7f7bV_roDyXz1V3Gou7MG-Z33G_nuanvv81VjajycGp0wy11KzBjYvAlEI3KVFdMoUjxJbEuolKc0ZTSmXpQJpWI7oZQzZkUwtPcjBcZxVMRZqpLE5e41o68530yvG4M-dWIe2RzkkCbC0IqxDGCV4hmNLdZvDFR6aSwUzmgald37DVJqqlE-op40VmaX4bfwcDl7ivq18LPFjTNRBowLKFm8ZLxp9C0-XkpvAe1eVLf19fQH6JCrMw |
| linkProvider | CAB International |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%98%BF%E8%8E%AB%E8%A5%BF%E6%9E%97%2F%E5%85%8B%E6%8B%89%E7%BB%B4%E9%85%B8%E9%92%BE%E8%81%94%E5%90%88%E5%B8%B8%E8%A7%84%E6%8A%97%E7%BB%93%E6%A0%B8%E8%8D%AF%E6%B2%BB%E7%96%97%E8%80%90%E5%A4%9A%E8%8D%AF%E8%82%BA%E7%BB%93%E6%A0%B8%E7%9A%84%E7%96%97%E6%95%88%E8%A7%82%E5%AF%9F&rft.jtitle=%E4%B8%AD%E5%9B%BD%E5%8C%BB%E9%99%A2%E7%94%A8%E8%8D%AF%E8%AF%84%E4%BB%B7%E4%B8%8E%E5%88%86%E6%9E%90&rft.au=%E9%83%AD%E8%95%8A+%E7%84%A6%E9%9B%AA%E5%B3%B0+%E9%99%88%E7%88%BD+%E7%BD%97%E7%90%B3&rft.date=2015&rft.issn=1672-2124&rft.issue=9&rft.spage=1142&rft.epage=1144&rft_id=info:doi/10.14009%2Fj.issn.1672-2124.2015.09.003&rft.externalDocID=667844985 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F86765X%2F86765X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgyyyypjyfx%2Fzgyyyypjyfx.jpg |